Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(0.84)
# 3,779
Out of 4,876 analysts
9
Total ratings
57.14%
Success rate
-18.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $17.44 | +43.35% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $5.44 | +763.97% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $1.30 | +284.62% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $23.38 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $2.59 | +749.42% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $18.40 | +519.57% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $16.90 | - | 2 | Nov 15, 2021 |
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $17.44
Upside: +43.35%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $5.44
Upside: +763.97%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $1.30
Upside: +284.62%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $23.38
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $2.59
Upside: +749.42%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $18.40
Upside: +519.57%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $16.90
Upside: -